Clinical significance and potential application of cuproptosis-related genes in gastric cancer

Table 2 Univariate and multivariate analysis of the correlation of differentially expressed cuproptosis-related gene expression with disease-specific survival among gastric cancer patients

Gene	Total, n	Univariate analysis		Multivariate analysis
		Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value
ATP7A	349	1.032 (0.656-1.625)	0.891
ATP7B	349	0.957 (0.776-1.180)	0.680
CDKN2A	349	1.019 (0.894-1.162)	0.774
DLAT	349	0.701 (0.471-1.043)	0.080	1.185 (0.708-1.982)	0.518
DLD	349	0.657 (0.415-1.039)	0.072	0.926 (0.529-1.622)	0.788
FDX1	349	0.668 (0.441-1.013)	0.057	0.722 (0.448-1.164)	0.181
GCSH	349	1.280 (0.863-1.900)	0.220
GLS	349	1.041 (0.788-1.376)	0.778
LIAS	349	0.509 (0.310-0.836)	0.008	0.578 (0.338-0.989)	0.045
LIPT1	349	1.117 (0.594-2.101)	0.731
LIPT2	349	1.014 (0.745-1.381)	0.928
MTF1	349	0.581 (0.329-1.023)	0.060	0.604 (0.321-1.135)	0.117
NFE2L2	349	0.584 (0.360-0.947)	0.029	0.709 (0.414-1.215)	0.211
NLRP3	349	1.082 (0.716-1.634)	0.710
PDHA1	349	0.676 (0.441-1.036)	0.072	0.780 (0.469-1.297)	0.338
PDHB	349	0.809 (0.465-1.408)	0.454
SLC31A1	349	0.768 (0.564-1.046)	0.094	1.029 (0.717-1.476)	0.878

CI: Confidence interval.